Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners; his previous experience includes 13 years as the VP, Global Sales, Marketing and Business Development at Nanosphere Inc.
In March 2019, Third Pole announced that it would collaborate with Actelion on the development of its inhaled nitric oxide (iNO) platform. The company also announced in August 2019 that it had received two new US patents for its iNO technology.
Athenson commented, “I am delighted to take the helm at Third Pole as the company transitions to its next stage of commercial development. Third Pole has made significant progress in its efforts to make portable inhaled nitric oxide (iNO) available in more settings and expand worldwide access to pharmaceutical iNO. I look forward to building on a culture defined by patient focus, accountability and teamwork to get Third Pole’s groundbreaking iNO generation and delivery system to patient communities struggling with the most serious, life-limiting, cardio-pulmonary diseases.”
Third Pole board member Ashleigh Palmer said, “Bill is the perfect leader to move Third Pole to the next level given his expertise in leading high-performance organizations transitioning from development to commercial operations. Bill’s extensive experience in building cross-functional therapeutic and device development operations and partnerships, from product concept through commercial execution across US, Europe, and Asia, is especially relevant to the future success of Third Pole.”
Read the Third Pole Therapeutics press release.
